Innate Pharma Closes €30M Private Placement at 15% Discount, Diluting Shareholders 18.76%
IPHA sits 81% above its 52-week low of $1.17 on light trading volume (0.2× avg).
Summary
Innate Pharma closed a €30 million private placement at €1.70 per share, a 15% discount, raising net proceeds of €27.6 million to fund its ADC pipeline. The offering dilutes existing shareholders by 18.76% but extends cash runway through Q1 2028.
Key Events · Financing and Capital Events · IPHA
-
€30M Private Placement Closed
Innate Pharma issued 17,647,059 new ordinary shares at €1.70 per share, raising €30.0 million gross and €27.6 million net after €2.4 million in fees. The offering was upsized from the initially announced €22.5 million.
-
18.76% Dilution to Existing Shareholders
The new shares represent approximately 18.76% of the company's share capital on a non-diluted basis. A shareholder holding 1% before the offering would hold 0.84% after completion.
-
Cash Runway Extended to Q1 2028
Combined with the $75 million Sobi upfront payment, the offering proceeds extend projected cash runway through Q1 2028, up from Q3 2027 prior to the offering. Current cash alone funds operations only through end of Q3 2026.
-
15% Discount to Market Price
The offering price of €1.70 per share represents a 15% discount to the volume-weighted average price over the five trading sessions preceding pricing (August 7-13, 2026).
Analysis · IPHA · Life Sciences
A €30 million private placement of 17.65 million new ordinary shares at €1.70 per share, a 15% discount to the five-day VWAP, was completed by Innate Pharma. The offering was upsized from the initially announced €22.5 million, reflecting strong institutional demand anchored by healthcare specialist investors and a €3 million commitment from existing shareholder Bpifrance. Net proceeds of €27.6 million extend the company's cash runway through Q1 2028 when combined with the $75 million Sobi upfront payment, funding the Phase 1 dose expansion of IPH4502 and preclinical ADC candidates. However, the issuance dilutes existing shareholders by approximately 18.76% on a non-diluted basis, and the shares cannot be deposited into the ADS program, creating a two-tier liquidity structure.
At the time of this filing, IPHA was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.3M. The 52-week trading range was $1.17 to $2.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.